Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Janice K Laramy"'
Autor:
Elizabeth C. Randall, Kristina B. Emdal, Janice K. Laramy, Minjee Kim, Alison Roos, David Calligaris, Michael S. Regan, Shiv K. Gupta, Ann C. Mladek, Brett L. Carlson, Aaron J. Johnson, Fa-Ke Lu, X. Sunney Xie, Brian A. Joughin, Raven J. Reddy, Sen Peng, Walid M. Abdelmoula, Pamela R. Jackson, Aarti Kolluri, Katherine A. Kellersberger, Jeffrey N. Agar, Douglas A. Lauffenburger, Kristin R. Swanson, Nhan L. Tran, William F. Elmquist, Forest M. White, Jann N. Sarkaria, Nathalie Y. R. Agar
Publikováno v:
Nature Communications, Vol 9, Iss 1, Pp 1-13 (2018)
Despite major drug discovery efforts, the therapeutic options for glioblastoma (GBM) remain inadequate. Here they analyze patient-derived xenograft model of GBM to quantitatively map distribution and cellular response to the EGFR inhibitor erlotinib,
Externí odkaz:
https://doaj.org/article/17219987055045cbbd74e20d4356a523
Autor:
Jann N. Sarkaria, William F. Elmquist, Paul A. Decker, Mark A. Schroeder, Ann C. Mladek, Katrina K. Bakken, Brett L. Carlson, Gautham Gampa, Minjee Kim, Janice K. Laramy, Karen E. Parrish, Shiv K. Gupta, Sani H. Kizilbash
Tesevatinib is a potent oral brain penetrant EGFR inhibitor currently being evaluated for glioblastoma therapy. Tesevatinib distribution was assessed in wild-type (WT) and Mdr1a/b(-/-)Bcrp(-/-) triple knockout (TKO) FVB mice after dosing orally or vi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::206b43b8da91279e8c66cb03985a2c44
https://doi.org/10.1158/1535-7163.c.6543372
https://doi.org/10.1158/1535-7163.c.6543372
Autor:
Jann N. Sarkaria, William F. Elmquist, Paul A. Decker, Mark A. Schroeder, Ann C. Mladek, Katrina K. Bakken, Brett L. Carlson, Gautham Gampa, Minjee Kim, Janice K. Laramy, Karen E. Parrish, Shiv K. Gupta, Sani H. Kizilbash
In vivo efficacy of tesevatinib 70 mg/kg in PDX GBM models
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c19b33dcf20878483aa29e0d9652653
https://doi.org/10.1158/1535-7163.22522416.v1
https://doi.org/10.1158/1535-7163.22522416.v1
Autor:
Mijin Moon, Yongje Shin, Ho Yeon Lee, Beomjin Hong, Jinhee Kim, Jun Lee, Janice K Laramy, Vijaykumar Vashi, Sook-Kyung Park
Publikováno v:
Neuro-Oncology. 24:vii233-vii234
Protein arginine methyltransferase 5 (PRMT5), a type II methyltransferase, regulates cellular processes such as survival, proliferation, and apoptosis by inducing symmetric arginine dimethylation of multiple cellular proteins involved in the regulati
Autor:
Paul A. Decker, Karen E. Parrish, Katrina K. Bakken, Jann N. Sarkaria, Janice K. Laramy, Mark A. Schroeder, Sani H. Kizilbash, Brett L. Carlson, Gautham Gampa, Minjee Kim, William F. Elmquist, Shiv K. Gupta, Ann C. Mladek
Publikováno v:
Mol Cancer Ther
Tesevatinib is a potent oral brain penetrant EGFR inhibitor currently being evaluated for glioblastoma therapy. Tesevatinib distribution was assessed in wild-type (WT) and Mdr1a/b(-/-)Bcrp(-/-) triple knockout (TKO) FVB mice after dosing orally or vi
Autor:
Jann N. Sarkaria, Gautham Gampa, Karen E. Parrish, William F. Elmquist, Janice K. Laramy, Minjee Kim, Richard C. Brundage
Publikováno v:
Drug Metab Dispos
Achieving an effective drug concentration in the brain is as important as targeting the right pathway when developing targeted agents for brain tumors. SAR405838 is a novel molecularly targeted agent that is in clinical trials for various solid tumor
Autor:
Jeffrey N. Agar, Jann N. Sarkaria, Aaron J. Johnson, Kristina B. Emdal, Nathalie Y. R. Agar, Fake Lu, Brian A. Joughin, Forest M. White, David Calligaris, Nhan L. Tran, X. Sunney Xie, Michael S. Regan, Shiv K. Gupta, Pamela R. Jackson, Raven J. Reddy, Walid M. Abdelmoula, Katherine A. Kellersberger, Douglas A. Lauffenburger, Aarti Kolluri, Alison Roos, Janice K. Laramy, Sen Peng, Minjee Kim, Brett L. Carlson, Ann C. Mladek, William F. Elmquist, Kristin R. Swanson, Elizabeth C. Randall
Publikováno v:
Nature Communications, Vol 9, Iss 1, Pp 1-13 (2018)
Nature Communications
Nature Communications
Therapeutic options for the treatment of glioblastoma remain inadequate despite concerted research efforts in drug development. Therapeutic failure can result from poor permeability of the blood-brain barrier, heterogeneous drug distribution, and dev
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 365:249-261
A compartmental blood-brain barrier (BBB) model describing drug transport across the BBB was implemented to evaluate the influence of efflux transporters on the rate and extent of the multikinase inhibitor ponatinib penetration across the BBB. In viv
Autor:
Linda J. Paradiso, Jann N. Sarkaria, Janice K. Laramy, Louis DePalatis, Nicholas Cook-Rostie, Minjee Kim, William F. Elmquist, Gautham Gampa
Publikováno v:
Drug Metabolism and Disposition. 46:658-666
Clinically meaningful efficacy in the treatment of brain tumors, including melanoma brain metastases (MBM), requires selection of a potent inhibitor against a suitable target, and adequate drug distribution to target sites in the brain. Deregulated c
Autor:
Debra H. Brinkmann, Jann N. Sarkaria, Leland S. Hu, Nathalie Y. R. Agar, Terence C. Burns, Paul D. Brown, Ian F. Parney, Janice K. Laramy, Timothy J. Kaufmann, Nadia N. Laack, Deanna H. Pafundi, Caterina Giannini, Kristin R. Swanson, Evanthia Galanis, Sani H. Kizilbash, William F. Elmquist, Jan C. Buckner
Publikováno v:
Neuro-Oncology. 20:184-191
The blood–brain barrier (BBB) excludes the vast majority of cancer therapeutics from normal brain. However, the importance of the BBB in limiting drug delivery and efficacy is controversial in high-grade brain tumors, such as glioblastoma (GBM). Th